Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | GALK1 | P51570 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38628 | 0.75 | MAOB (0.51) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL787149 | 0.75 | TOP2A (0.53) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL10411212 | 0.75 | — | — | |
| SCHEMBL7754182 | 0.73 | KDM4E (0.37) | RAB9AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL1136612 | 0.72 | MAOB (0.48) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL4337978 | 0.72 | LIMK1 (0.39) | METAP2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL915916 | 0.72 | HSD17B10 (0.36) | MAOBRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL12854020 | 0.71 | MAOB (0.71) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL61411 | 0.71 | MAOB (0.71) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL290970 | 0.70 | ESR1 (0.43) | MAOBMAPTKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4746878-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| EP-1581518-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | claimed |
| JP-2006514027-A | — | — | 2006-04-27 | — | — | JP | claimed |
| EP-1581518-A2 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056799-A2 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | claimed |
| US-10710992-B2 | Substituted pyridinones as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2020-07-14 | — | — | US | disclosed |
| US-20170320866-A1 | SUBSTITUTED PYRIDINONES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-11-09 | — | — | US | disclosed |
| EP-1581518-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-1651232-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1651232-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-0114306-B1 | HIGH SENSITIVITY AND DEVELOPABILITY MULTILAYER COLOR PHOTOGRAPHIC MATERIAL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0114306-A2 | High sensitivity and developability multilayer color photographic material | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320866-A1 | SUBSTITUTED PYRIDINONES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAOB 1907/4885MAOA 3377/4885RAB9A 3287/4885 |
| US-10710992-B2 | Substituted pyridinones as bromodomain inhibitors | BRD4, BRD3, BRD1 | MAOB 1907/4885MAOA 3377/4885RAB9A 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.